TNF-α 타깃 프로그램 | 바이오모아

Data Tier

ADC · Antibody · CGT를 FDA 승인, ORR·PASI·ACR·BCVA, 임상 등록 규모, Phase 3, 조회수 등 공개 데이터로 복합 점수화합니다. S–C 티어와 가점 요인은 규칙 기반(Data Tier)이며 LLM이 아닙니다.

상위 4개 비교 RSS 구독 차세대 추천

S Tier1개

승인·효능·임상 규모·관심도 종합 상위

Tier	프로그램	Modality	점수	가점 요인	요약	분석
S	adalimumab (Humira) AbbVie · TNF-α	Antibody	97	FDA 승인ORR 98.85%임상 420건등록 146,421명Phase 3 147건	Antibody — FDA 승인 · ORR 98.85% · 임상 420건	Antibody로 FDA 승인을 받아 상용화 단계에 있습니다. 보고된 ORR 98.85%는 동일 TNF-α·Rheumatoid arthritis, ps군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 146,421명 규모.

S97점

adalimumab

Antibody · AbbVie · TNF-α

Antibody — FDA 승인 · ORR 98.85% · 임상 420건

FDA 승인 · ORR 98.85% · 임상 420건 · 등록 146,421명

Antibody로 FDA 승인을 받아 상용화 단계에 있습니다. 보고된 ORR 98.85%는 동일 TNF-α·Rheumatoid arthritis, ps군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 146,421명 규모.

B Tier1개

중간 수준 — 확장 데이터 또는 초기 단계

Tier	프로그램	Modality	점수	가점 요인	요약	분석
B	etanercept (Enbrel) Amgen · TNF	Antibody	96	FDA 승인ORR 73.4%임상 117건등록 79,607명Phase 3 20건	Antibody — FDA 승인 · ORR 73.4% · 임상 117건	Antibody로 FDA 승인을 받아 상용화 단계에 있습니다. 보고된 ORR 73.4%는 동일 TNF·RA, psoriasis, psoriatic군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 79,607명 규모.

B96점

etanercept

Antibody · Amgen · TNF

Antibody — FDA 승인 · ORR 73.4% · 임상 117건

FDA 승인 · ORR 73.4% · 임상 117건 · 등록 79,607명

Antibody로 FDA 승인을 받아 상용화 단계에 있습니다. 보고된 ORR 73.4%는 동일 TNF·RA, psoriasis, psoriatic군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 79,607명 규모.

C Tier2개

초기/제한적 데이터 — 추적 관찰

Tier	프로그램	Modality	점수	가점 요인	요약	분석
C	Infliximab Janssen · Crohn Disease	Antibody	63	승인 단계ORR 54.5%임상 283건등록 61,487명Phase 3 71건	Antibody — 승인 단계 · ORR 54.5% · 임상 283건	Antibody 초기·전임상 단계로 데이터가 제한적입니다. 보고된 ORR 54.5%는 동일 Crohn Disease·Cytokine Release Syndrom군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 61,487명 규모.
C	TNFi (Tumor Necrosis Factor inhibitor) medication Bristol-Myers Squibb · Polyarticular Course Juvenile Idiopathic	Antibody	45	Phase 3ORR 6.35%임상 94건등록 289,950명Phase 3 8건	Antibody — Phase 3 · ORR 6.35% · 임상 94건	Antibody Phase 3로 후기 임상을 진행 중입니다. 보고된 ORR 6.35%는 동일 Polyarticular Course Juvenile Idiopathic·Polyarticular Course Juv군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 289,950명 규모.

C63점

Infliximab

Antibody · Janssen · Crohn Disease

Antibody — 승인 단계 · ORR 54.5% · 임상 283건

승인 단계 · ORR 54.5% · 임상 283건 · 등록 61,487명

Antibody 초기·전임상 단계로 데이터가 제한적입니다. 보고된 ORR 54.5%는 동일 Crohn Disease·Cytokine Release Syndrom군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 61,487명 규모.

C45점

TNFi (Tumor Necrosis Factor inhibitor) medication

Antibody · Bristol-Myers Squibb · Polyarticular Course Juvenile Idiopathic

Antibody — Phase 3 · ORR 6.35% · 임상 94건

Phase 3 · ORR 6.35% · 임상 94건 · 등록 289,950명

Antibody Phase 3로 후기 임상을 진행 중입니다. 보고된 ORR 6.35%는 동일 Polyarticular Course Juvenile Idiopathic·Polyarticular Course Juv군에서 경쟁력 있는 신호입니다. 등록 환자 합산 약 289,950명 규모.

TNF-α 타깃

Data Tier

프로그램 (156)

adalimumab (Humira, Hyrimoz, Amjevita)

Infliximab (Infliximab)

etanercept (Enbrel, Erelzi)

Humira (Adalimumab, Adalimumab (Humira))

Remicade (Infliximab, Infliximab (Remicade))

infliximab (Remicade, Remicade (infliximab))

adalimumab (Humira, Adalimumab treatment arm)

Azathioprine + infliximab (Azathioprine + infliximab)

Anti TNF therapy including infliximab (Anti TNF therapy including infliximab)

Topical infliximab (Topical infliximab)

adalimumab (Humira, Humira (adalimumab))

adalimumab (Humira, Adalimumab Ab)

ADA (Adalimumab, Adalimumab (ADA))

adalimumab (Humira, Adalimumab Dose Intensification)

adalimumab (Humira, adalimumab-EU source)

adalimumab (Humira, Open-label Adalimumab)

infliximab, azathioprine (infliximab, azathioprine)

D2E7 (adalimumab, adalimumab (D2E7))

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

up to 9 months exposure (adalimumab, adalimumab (up to 9 months exposure))

Akkermansia muciniphila + Infliximab (Akkermansia muciniphila + Infliximab)

IFX (Infliximab, Infliximab (IFX))

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Standard infliximab intravenous therapy (Standard infliximab intravenous therapy)

Methotrexate + Infliximab (Methotrexate + Infliximab)

adalimumab (Humira, TNFa Antagonist - Adalimumab)

adalimumab (Humira, Adalimumab PFS and Pen)

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

TNFa Antagonist - Infliximab (TNFa Antagonist - Infliximab)

etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept (bDMARD withdrawal, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept))

TNF-α 타깃

Data Tier

프로그램 (156)

adalimumab (Humira, Hyrimoz, Amjevita)

Infliximab (Infliximab)

etanercept (Enbrel, Erelzi)

Humira (Adalimumab, Adalimumab (Humira))

Remicade (Infliximab, Infliximab (Remicade))

infliximab (Remicade, Remicade (infliximab))

adalimumab (Humira, Adalimumab treatment arm)

Azathioprine + infliximab (Azathioprine + infliximab)

Anti TNF therapy including infliximab (Anti TNF therapy including infliximab)

Topical infliximab (Topical infliximab)

adalimumab (Humira, Humira (adalimumab))

adalimumab (Humira, Adalimumab Ab)

ADA (Adalimumab, Adalimumab (ADA))

adalimumab (Humira, Adalimumab Dose Intensification)

adalimumab (Humira, adalimumab-EU source)

adalimumab (Humira, Open-label Adalimumab)

infliximab, azathioprine (infliximab, azathioprine)

D2E7 (adalimumab, adalimumab (D2E7))

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

up to 9 months exposure (adalimumab, adalimumab (up to 9 months exposure))

Akkermansia muciniphila + Infliximab (Akkermansia muciniphila + Infliximab)

IFX (Infliximab, Infliximab (IFX))

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Standard infliximab intravenous therapy (Standard infliximab intravenous therapy)

Methotrexate + Infliximab (Methotrexate + Infliximab)

adalimumab (Humira, TNFa Antagonist - Adalimumab)

adalimumab (Humira, Adalimumab PFS and Pen)

proposed biosimilar to infliximab (SB2, SB2 (proposed biosimilar to infliximab))

TNFa Antagonist - Infliximab (TNFa Antagonist - Infliximab)

etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept (bDMARD withdrawal, bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept))

TNF-α 타깃

Data Tier

프로그램 (156)

adalimumab (Humira, Hyrimoz, Amjevita)

Infliximab (Infliximab)

etanercept (Enbrel, Erelzi)

Humira (Adalimumab, Adalimumab (Humira))

Remicade (Infliximab, Infliximab (Remicade))

infliximab (Remicade, Remicade (infliximab))

adalimumab (Humira, Adalimumab treatment arm)

Azathioprine + infliximab (Azathioprine + infliximab)

Anti TNF therapy including infliximab (Anti TNF therapy including infliximab)

Topical infliximab (Topical infliximab)

adalimumab (Humira, Humira (adalimumab))